• Tranexamic Acid: Assay Design for Fibrinolysis

  2026-10-01

  Tranexamic Acid is an antifibrinolytic agent whose value in fibrinolysis research depends on separating plasmin inhibition from clot formation, cell adhesion, and biomaterial effects. This guide translates the mechanism and a 2024 wound-dressing study into practical assay-design decisions.

• EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag)

  2026-10-01

  Build a controlled mouse OX40L co-stimulation assay around transient mRNA expression, HA-based verification, and receptor-dependent T-cell readouts. This workflow separates what R1078 can establish mechanistically from what the CD80/4-1BBL reference study demonstrated in a different experimental system.

• Heparin sodium in Coagulation & HSPG Research

  2026-09-30

  Heparin sodium supports reproducible anti-factor Xa and aPTT workflows while offering a carefully controlled way to investigate heparan sulfate proteoglycan-dependent nanovesicle uptake. This guide connects established coagulation assays with an exploratory Sertoli-cell application, emphasizing controls, optimization, and interpretation limits.

• Dabigatran etexilate Research Workflows

  2026-09-30

  Build reproducible thrombin, plasma-clotting, and platelet assays with Dabigatran etexilate while accounting for its oral-prodrug behavior and limited water solubility. This workflow separates target engagement from carboxylesterase-dependent conversion, helping researchers connect mechanistic data with anticoagulant and atrial fibrillation models.

• HyperFluor 488 for Vaccine Antibody Studies

  2026-09-29

  Discover how the HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody can support rigorous antibody-detection workflows in vaccine research. This article connects fluorescent assay design with the variant-focused RQ3025 preclinical study while clarifying what binding-antibody data can—and cannot—demonstrate.

• rhBNP, SCLY, and Ferroptosis in Renal IR Injury

  2026-09-29

  The reference study identifies selenocysteine lyase (SCLY)-dependent selenium recycling as a central mechanism through which recombinant human brain natriuretic peptide (rhBNP) limits ferroptosis during renal ischemia-reperfusion injury. Its combination of clinical analysis, rat modeling, transcriptomics, and targeted cell experiments supports SCLY as a mechanistic and potentially therapeutic target in acute kidney injury.

• Berberrubine and the Vitamin K Cycle in Thrombosis

  2026-09-28

  The reference study combines a mouse thrombosis model, untargeted metabolomics, hemostasis testing, and molecular docking to investigate how berberrubine inhibits thrombus formation. Its central contribution is the identification of vitamin K catalytic-cycle regulation, involving VKOR and GGCX, as a mechanistic explanation for berberrubine’s antithrombotic activity.

• NF449 Reveals Dose-Dependent Platelet P2 Receptor Blockade

  2026-09-28

  The study identifies NF449 as a potent functional antagonist of platelet P2X1 and shows that its effects on platelet responses and experimental thrombosis depend on dose. Its comparison of P2X1, P2Y1, and P2Y12 responses highlights both the value and the limits of targeting one purinergic receptor subtype.

• Vancomycin hydrochloride: Assay Decisions That Hold Up

  2026-09-27

  A practical, scenario-based guide to using Vancomycin hydrochloride (SKU B1223) in Gram-positive bacterial inhibition and susceptibility workflows—while distinguishing those applications from mammalian cell viability and cytotoxicity assays. It covers mechanism, formulation, interpretation, protocol parameters, and evidence-based product selection.

• Heparin Sodium in HSPG-Dependent Nanovesicle Studies

  2026-09-26

  Heparin sodium is best understood here as a mechanistic probe—not evidence that anticoagulation treats testicular injury. This article explains how to separate coagulation readouts from HSPG-dependent nanovesicle uptake experiments and design more interpretable controls.

• Sulfaphenazole and Perfusion-First Wound Research

  2026-09-25

  Sulfaphenazole is a CYP2C9 inhibitor with applications beyond enzyme assays. Explore how perfusion-focused injury research connects CYP2C inhibition to tissue outcomes—and how to design experiments that distinguish mechanism from therapeutic effect.

• Phenothiazines, ROS, and Autophagy in Macrophage Defense

  2026-09-25

  Qiu and colleagues report that phenothiazines increase macrophage antibacterial activity alongside greater lysosomal activity, reactive oxygen species (ROS), and autophagy; blocking ROS or autophagy weakened the effect. Their perphenazine findings in a Salmonella infection model support further study of host-directed antibacterial strategies, but do not establish that dopamine D2 receptor inhibition or any single phenothiazine explains the class effect.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-09-24

  A study in hepatocellular carcinoma links tumor-cell exosomal SNORD52 with M2-like macrophage polarization and increased JAK2/STAT6 pathway activity. Its donor-cell, extracellular RNA, and recipient-macrophage framework offers a basis for investigating tumor–immune communication, while leaving important questions about in vivo relevance and pathway specificity open.

• 3-Bromopyruvate Reverses Cetuximab Resistance in CRC

  2026-09-24

  A 2023 study reports that 3-bromopyruvate combined with cetuximab suppresses growth in colorectal cancer models with intrinsic or acquired cetuximab resistance. The findings connect FOXO3a restoration to autophagy-associated ferroptosis and apoptosis, offering a mechanistic rationale for the combination while leaving important questions about clinical transfer unresolved.

• Heparin Sodium in Nanovesicle Assay Design

  2026-09-23

  Heparin sodium is a glycosaminoglycan anticoagulant, but its value in nanovesicle research depends on separating coagulation readouts from cell-entry mechanisms. This article examines what a Sertoli-cell study establishes—and what it does not—before outlining cautious, testable assay decisions.

8665 records 1/578 page Next 12345 下5页 Last page